secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2026-08-25T20:12:59+00:00
Accession:  0001437749-26-028916
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart creates two new board committees, appoints members
---------------------------------------------------------

- On Aug 21, 2026, board formed Clinical and Regulatory Affairs Committee and Stockholder Engagement Committee.
- Dr. James B. Breitmeyer chairs Clinical/Regulatory; Dr. David Wheadon also appointed as member.
- W. Mark Watson named Interim Chair of Stockholder Engagement Committee; Steven Lo also a member.
- New director to chair Stockholder Engagement Committee per July 1, 2026 Cooperation Agreement.
- Committees oversee clinical/regulatory programs and stockholder relations respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774926028916/0001437749-26-028916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774926028916/vxrt20260824_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-028916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer